AstraZeneca has sold its 7.7 percent stake in Moderna for more than $1 billion
image for illustrative purpose
Moderna, whose vaccine is cleared for emergency use against COVID-19 in the United States, said last week it was expecting sales of $18.4 billion from its coronavirus vaccine this year.
AstraZeneca Plc has sold its 7.7 percent stake in Moderna Inc for more than $1 billion after the US biotechnology company's shares soared on the back of its coronavirus vaccine breakthrough. The report added that it was not clear over what period British-based AstraZeneca sold its holding in Moderna. AstraZeneca and Moderna did not immediately respond to requests for comment.
AstraZeneca is retaining partnership with Moderna on other disease treatments and could sell its AstraZeneca/Oxford University COVID-19 vaccine on a commercial basis in future if the virus becomes endemic, the sources said.
Moderna, whose vaccine is cleared for emergency use against COVID-19 in the United States, said last week it was expecting sales of $18.4 billion from its coronavirus vaccine this year.
